All News from Accelerate Diagnostics

All News

Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results

Jan 13, 2020 — TUCSON, Ariz., Jan. 13, 2020 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter and year ending December 31, 2019. Highlights for the fourth quarter and full-year 2019 are presented below. 2019 Fourth Quarter and Full-Year Financial Highlights Commercially contracted instruments were 137 in the fourth quarter and 304 […]

Continue reading ›

Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

Oct 03, 2019 — From IDWeek™, the annual meeting of the Infectious Diseases Society of America (IDSA) held in Washington, DC October 2 – 6. TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that […]

Continue reading ›

Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

Sep 18, 2019 — Accelerate Diagnostics, Inc. recently highlighted the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019.   “We are thrilled with the results of these clinical studies, which provide further evidence of the clinical value of Pheno,” commented Dr. Romney Humphries, Chief Scientific Officer of […]

Continue reading ›

Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit

Aug 02, 2019 — Today we announced the release and CE marking of our latest Accelerate PhenoTest™ BC kit, declaring conformity to the European Directive 98/79/EC on in vitro diagnostic medical devices. The new CE-IVD Accelerate PhenoTest™ BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, and trimethoprim-sulfamethoxazole […]

Continue reading ›

University of Iowa Hospitals & Clinics announces adoption of Accelerate Pheno

Jan 16, 2019 — University of Iowa Hospitals & Clinics recently shared their adoption of the Accelerate Pheno™ system as a “new technology that helps diagnose and treat sepsis—a potentially life-threatening infection in the blood—faster than ever before.” Get the full story from UI Health Care Quick story excerpt: “Every hour counts,” explains Bradley Ford, MD, PhD, medical director […]

Continue reading ›

Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results

Jan 06, 2019 — Added 117 commercially contracted U.S. instruments in Q4, doubling the regional installed base TUCSON, Ariz., Jan. 6, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S. instruments placed under commercial contract during the fourth quarter, and […]

Continue reading ›

Accelerate Diagnostics reports Q3 2018 financial results

Nov 06, 2018 — Revenue Placements up 40 Percent in U.S., Total Revenue up 64 Percent TUCSON, Ariz., Nov. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending September 30, 2018. The company reported a 40% increase in U.S. instruments placed under commercial contract, and revenue for the quarter of $1.3 million, an […]

Continue reading ›

Accelerate Diagnostics Receives New Innovative Technology Contract from Vizient for the Accelerate Pheno™ System

Aug 07, 2018 — TUCSON, Ariz., Aug. 7, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. announced today that it received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the United States. The contract was based on a recommendation of the Accelerate Pheno™ system by hospital experts in this category who serve on […]

Continue reading ›

Accelerate Diagnostics reports Q2 2018 financial results

Aug 06, 2018 — Revenue up 142 Percent, Global install base up 25 Percent TUCSON, Ariz., Aug. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending June 30, 2018. The company posted revenue of $1.7 million, up 142% from the prior year quarter, and reported a record number of new agreements signed in […]

Continue reading ›

Accelerate Diagnostics Will Host Symposia at ASM Microbe 2018

Jun 06, 2018 — Accelerate Diagnostics, Inc. announced today it will host symposia on the clinical opportunities of integrating fast, phenotypic susceptibility testing into antimicrobial stewardship programs and its impact on the management of patients with bacteremia at the American Society of Microbiologist Microbe 2018 forum in Atlanta, Georgia.

Continue reading ›